The global health complex

BioSocieties

Volumn 6, Issue 1, 2011, Pages 1-9

  McGoey, Linsey ^a   Reiss, Julian ^b   Wahlberg, Ayo ^c  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84860389687     PISSN: 17458552     EISSN: 17458560     Source Type: Journal    
DOI: 10.1057/biosoc.2010.45     Document Type: Review

References (33)

1. Benatar, S. (2009) Global health: Where to now? Global Health Governance 2: Online publication http://ghgj.org/benatar2.wherenow.htm.
2. Biehl, J. (2007) Pharmaceuticalization: AIDS treatment and global health politics. Anthropological Quarterly 4: 1083-1126.
3. Birn, A.-E. (2005) Gates's grandest challenge: Transcending technology as public health ideology. Lancet, 366: 1357-1358.
4. Brenner, R. (1998) The economics of global turbulence: A special report on the world economy, 1950-98. New Left Review 229(May/June): 1-261.
5. Buse, K. and Harmer, A. (2004) Power to the partners? The Politics of Public-Private Health Partnerships Development 47(2): 49-56.
6. ClinicalTrials.gov. (2010) Paxil Japanese post marketing paediatric study in depression (double-blind, placebo controlled study), http://clinicaltrials. gov/ct2/show/study/NCT00812812, accessed 17 November 2010.
7. Correa, C. (2006) Implications of bilateral free trade agreements on access to medicines. Bulletin of the World Health Organization 84(5): 399-404.
8. Cooper, M. (2008) Life as Surplus: Biotechnology and Capitalism in the Neoliberal Era. Seattle, London: University of Washington Press.
9. Ecks, S. (2008) Global pharmaceutical markets and corporate citizenship: The case of Novartis' anti-cancer drug Glivec. BioSocieties 3: 165-181.
10. Edwards, J. (2010) Glaxo is testing Paxil on 7-year-olds despite well known suicide risks. BNET, 21 May http://www.bnet.com/blog/drug-business/glaxo- is-testing-paxil-on-7-year-olds-despite-well-known-suicide-risks/4836.
11. Fidler, D. (2008) After the revolution: Global health politics in a time of economic crisis and threatening future trends. Global Health Governance 2(Fall 2008/Spring 2009), www.ghj.org.
12. Hollis, A. and Pogge, T. (2008) The Health Impact Fund: Making New Medicines Accessible for All. Incentives for Global Health, http://www. incentivesforglobalhealth.org
13. Kickbusch, I. (2006) Mapping the future of public health: Action on global health. Canadian Journal of Public Health 97: 6-8. (Pubitemid 43279894)
14. Lakoff, A. (2010) Two regimes of global health. Humanity: An International Journal of Human Rights, Humanitarianism, and Development 1(1): 59-79.
15. Lakoff, A. and Collier, S. (eds.)(2008) Biosecurity Interventions: Global Health and Security in Question. New York: Columbia University Press
16. Lancet. (2009) Editorial: Pharmaceuticals, patents, publicity . and philanthropy? Lancet 373: 693.
17. Lee, K., Buse, K. and Fustukian, S. eds. (2002) Health Policy in a Globalising World. Cambridge, UK: Cambridge University Press.
18. Lexchin, J. (2010) One step forward, one step sideways? Expanding research capacity of neglected diseases. BMC International Health and Human Rights 10
19. BMC International Health and Human Rights, 10, http://www.biomedcentral. com/1472-698X/10/20. Mahajan, M. (2008) Designing epidemics: Models, policy-making, and global foreknowledge in India's AIDS epidemic. Science and Public Policy 35: 585-596.
20. Mauss, M. (1990) The Gift: The Form and Reason for Exchange in Archaic Societies. New York/London: W.W. Norton
21. McCoy, D., Kembhavi, G., Patel, J. and Luintel, A. (2009) Global health funding: How much, where it comes from, and where it goes. Health Policy and Planning 24(6): 407-417.
22. McGoey, L. and Jackson, E. (2009) Seroxat and the suppression of trial data: Regulatory failure and the uses of legal ambiguity. Journal of Medical Ethics 36(2): 107-112.
23. McNeil, D. (2010) Ally for the poor in an unlikely corner. New York Times, 9 February.
24. Mosse, D. and Lewis, D. (2005) The Aid Effect: Giving and Governing in International Development. London: Pluto Press.
25. Peterson, K. (2001) Benefit sharing for all? Bioprospecting NGOs, intellectual property rights, new governmentalities. Polar 24: 78-91.
26. Pharmaceutical R&D Policy Project. (2005) The New Landscape of Neglected Disease Drug Development. London: London School of Economics/Wellcome Trust.
27. Pogge, T. (2005) Human rights and global health: A research program. Metaphilosophy 36(1/2): 182-209.
28. Redfield, P. (2008) Doctors without borders and the moral economy of pharmaceuticals. In: A. Bullard (ed.) Human Rights in Crisis. Aldershot, UK: Ashgate.
29. Reiss, J. and Kitcher, P. (2009) Biomedical research, neglected diseases, and well-ordered science. Theoria 24(3): 263-282.
30. Schumpeter, J. (1976 1942) Capitalism, Socialism and Democracy. New York: HarperPerenniel.
31. Sridhar, D. and Batniji, R. (2008) Misfinancing global health: The case for transparency in disbursements and decision-making. Lancet 372: 1185-1191.
32. Sridhar, D. (2009) Global health: WHO can lead. World Today (Chatham House magazine), February.
33. Taylor, L. (2010) German pharma price cut plans move closer Pharma Times. Pharma Times http://www.pharmatimes.com/Article/10-11-15/German-pharma-price- cut-plans-move-closer.aspx.15 November.